DeanFBajorinMD

Genitourinary Oncology

Professor of Medicine, Weill Cornell Medical College

Overview of Dr. Bajorin

Dr. Dean Bajorin is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from New York Medical College and has been in practice 39 years. Dr. Bajorin accepts several types of health insurance, listed below. He is one of 464 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
1275 York Avenue
New York, NY 10021
Book by Phone+1(209) 727-4906
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
University of ConnecticutResidency, Internal Medicine, 1978 - 1981
New York Medical CollegeClass of 1978

Certifications & Licensure

NJ State Medical License 2020 - 2025
NY State Medical License 1985 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2011
New York Magazine: Top Doctors Castle Connolly, 2010
Fellow (FACP) American College of Physicians, 1999
Join now to see all

Clinical Trials

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Start of enrollment: 1995 May 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer Start of enrollment: 1996 Nov 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer Start of enrollment: 1997 Sep 01
Completed
Phase 1, Phase 2
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer Start of enrollment: 1997 Sep 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer Start of enrollment: 1997 Dec 01
Completed
Phase 1
Arsenic Trioxide in Treating Patients With Urothelial Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Bladder Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 3
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas Start of enrollment: 2003 Oct 28
Completed
Phase 1
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Start of enrollment: 2006 Sep 01
Completed
Phase 2
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment Start of enrollment: 2007 Mar 01
Completed
Phase 2
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma Start of enrollment: 2006 May 01
Completed
Phase 2
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium Start of enrollment: 2008 Dec 05
Completed
Phase 2
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2009 Feb 01
Completed
Phase 2
A Genotype-Phenotype Urothelial Cancer Registry Start of enrollment: 2009 May 01
Recruiting
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2010 Aug 01
Completed
Phase 1
Tesetaxel for Previously Treated Patients With Bladder Cancer Start of enrollment: 2010 Sep 01
Unknown status
Phase 2
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium Start of enrollment: 2012 Mar 01
Completed
Phase 2
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 2
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy Start of enrollment: 2012 Jun 01
Terminated
Phase 2
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Lenalidomide Maintenance in Plasma Cell Myeloma Start of enrollment: 2015 Aug 31
Active, not recruiting
Phase 2
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] Start of enrollment: 2018 Jun 27
Recruiting
Phase 2
Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) Start of enrollment: 2018 Aug 01
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Ketterin...
Wesley Yip, Melissa J Assel, Nathan C Wong, Andrew T Tracey, Ricardo G Alvim, Lucas Nogueira, Nima Almassi, Nirmish Singla, Timothy N Clinton, Daniel D Sjoberg, Hikmat...> ;Urology Practice. 2024 Mar 1
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
Brahmer, J., Long, G., Hamid, O., Garon, E., Herbst, R., Andre, T., Armand, P., Bajorin, D., Bellmunt, J., Burtness, B., Choueiri, T., Cohen, E., Diaz, L., Shitara, K....> ;European Journal of Cancer. 2024 Mar 1
Corrigendum to "Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combin...
Galsky, M., Bajorin, D., Witjes, J., Gschwend, J., Tomita, Y., Nasroulah, F., Li, J., Collette, S., Valderrama, B., Grimm, M., Appleman, L., Gravis, G., Necchi, A., Ye...> ;European Urology. 2024 Mar 1
Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
Samuel A Funt, Andrea Knezevic, Kaamilah Wilson, Maria Bromberg, Amy Budnick, Kerri L O'Connor, Deaglan J McHugh, Erik Larsen, Dean F Bajorin, Robert J Motzer, Emily S...> ;Cancer. 2023 Dec 15
2 citations
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Brendan J Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A Funt, Chung-Han Lee, David H Aggen, Ashley M Regazzi, Ziyu Chen, Michael Lattanzi, ...> ;Clinical Cancer Research. 2023 Nov 14
2 citations
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
Rami S Vanguri, James W Smithy, Yanyun Li, Mingqiang Zhuang, Colleen A Maher, Nathaniel Aleynick, Xiyu Peng, Hikmat Al-Ahmadie, Samuel A Funt, Jonathan E Rosenberg, Go...> ;The Journal of Pathology. 2023 Nov 1
11 citations
Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
Stella Koutros, Lambertus A Kiemeney, Parichoy Pal Choudhury, Roger L Milne, Evangelina Lopez de Maturana, Yuanqing Ye, Vijai Joseph, Oscar Florez-Vargas, Lars Dyrskjø...> ;European Urology. 2023 Jul 1
2 citations
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.
Dean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, Michael Schenker, Begoña P Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebret, Shahrokh F Shariat, Se...> ;Future Oncology. 2023 Feb 1
6 citations
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Scor...
Matthew D Galsky, Dean F Bajorin, Johannes Alfred Witjes, Jürgen E Gschwend, Yoshihiko Tomita, Federico Nasroulah, Jun Li, Sandra Collette, Begoña P Valderrama, Marc-O...> ;European Urology. 2023 May 1
2 citations
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
Wesley Yip, Daniel D Sjoberg, Lucas M Nogueira, Andrew T Tracey, Ricardo G Alvim, Peter A Reisz, Quinlan Demac, Nicole E Benfante, Rand W Vanden Berg, Kwanghee Kim, Hi...> ;The Journal of Urology. 2023 May 1
15 citations
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
Jonathan A Coleman, Wesley Yip, Nathan C Wong, Daniel D Sjoberg, Bernard H Bochner, Guido Dalbagni, S Machele Donat, Harry W Herr, Eugene K Cha, Timothy F Donahue, Eug...> ;Journal of Clinical Oncology. 2023 Mar 10
1 citations
Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.
Joshua I Warrick, Wenhuo Hu, Hironobu Yamashita, Vonn Walter, Lauren Shuman, Jenna M Craig, Lan L Gellert, Mauro A A Castro, A Gordon Robertson, Fengshen Kuo, Irina Os...> ;Nature Communications. 2022 Dec 23
6 citations
Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.
Timothy N Clinton, Ziyu Chen, Hannah Wise, Andrew T Lenis, Shweta Chavan, Mark T A Donoghue, Nima Almassi, Carissa E Chu, Shawn Dason, Pavitra Rao, James A Rodrigues, ...> ;Cell Reports. 2022 Dec 20
9 citations
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.
Joshua I Warrick, Wenhuo Hu, Hironobu Yamashita, Vonn Walter, Lauren Shuman, Jenna M Craig, Lan L Gellert, Mauro A A Castro, A Gordon Robertson, Fengshen Kuo, Irina Os...> ;Nature Communications. 2022 Nov 2
1 citations
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in th...
Yoshihiko Tomita, Ko Kobayashi, Go Kimura, Mototsugu Oya, Hirotsugu Uemura, Hiroyuki Nishiyama, Matthew D Galsky, Federico Nasroulah, Sandra Collette, Edward Broughton...> ;Japanese Journal of Clinical Oncology. 2023 Jan 6
31 citations
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.
Ramin Sedaghat Herati, David A Knorr, Laura A Vella, Luisa Victoria Silva, Lakshmi Chilukuri, Sokratis A Apostolidis, Alexander C Huang, Alexander Muselman, Sasikanth ...> ;Nature Immunology. 2022 Aug 1
3 citations
Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
Eugene J Pietzak, Karissa Whiting, Preethi Srinivasan, Chaitanya Bandlamudi, Aliya Khurram, Vijai Joseph, Aleksandra Walasek, Emily Bochner, Timothy Clinton, Nima Alma...> ;Clinical Cancer Research. 2022 Oct 3
13 citations
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
Jonathan E Rosenberg, Se Hoon Park, Vadim Kozlov, Tu V Dao, Daniel Castellano, Jian-Ri Li, Som D Mukherjee, Kathryn Howells, Hannah Dry, Mark C Lanasa, Ross Stewart, D...> ;Journal of Clinical Oncology. 2023 Jan 1
7 citations
Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma.
Lucas M Nogueira, Wesley Yip, Melissa J Assel, Andrew T Tracey, Nathan C Wong, Ricardo G Alvim, Hikmat Al-Ahmadie, Dean F Bajorin, Jonathan A Coleman> ;The Journal of Urology. 2022 Oct 1
18 citations
Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z., de Andrade, K., Bajorin, D., Bandlamudi, C., Callahan, M., Funt, S., Hadrup, S., Holm, J., Rosenberg, J., Shah, S., ...> ;Nature. 2022 Jun 1
1 citations
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z., de Andrade, K., Bajorin, D., Bandlamudi, C., Callahan, M., Funt, S., Hadrup, S., Holm, J., Rosenberg, J., Shah, S., ...> ;Nature. 2022 Jun 1
4 citations
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
Nima Almassi, Karissa Whiting, Antoun Toubaji, Andrew T Lenis, Emmet J Jordan, Helen Won, Ashley M Regazzi, Ying-Bei Chen, Anuradha Gopalan, Sahussapont J Sirintrapun,...> ;JCO Precision Oncology. 2022 Jun 1
16 citations
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A Climent, Daniel P Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N Sternberg, Peter H O'Donnell, Tho...> ;Clinical Cancer Research. 2022 May 13
6 citations
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.
Min Yuen Teo, Brendan J Guercio, Arshi Arora, Xueli Hao, Ashley M Regazzi, Timothy Donahue, Harry W Herr, Alvin C Goh, Eugene K Cha, Eugene Pietzak, Sherri M Donat, Gu...> ;Clinical Genitourinary Cancer. 2022 Oct 1
1 citations
Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Min Yuen Teo, Hikmat Al-Ahmadie, Kenneth Seier, Christopher Tully, Ashley M Regazzi, Eugene Pietzak, David B Solit, Satish Tickoo, Victor Reuter, Eugene K Cha, Harry H...> ;British Journal of Cancer. 2022 May 1
Join now to see all

Press Mentions

Immunotherapy After Bladder Cancer Surgery May Reduce Recurrence, Study ShowsJune 4th, 2021
Women Leaders at MSK: Diane Reidy-LagunesApril 2nd, 2021
Adjuvant Therapy for Improved Disease-Free Survival for Patients with Muscle-Invasive Urothelial Carcinoma Following Radical Surgery - Checkmate 274 - Petros GrivasMarch 28th, 2021
Join now to see all

Grant Support

Cancer Chemotherapy Training ProgramNational Cancer Institute2006–2011
Mskcc Clinical Research Methodology CurriculumNational Center For Research Resources2005–2007
Clinical Research Methodology CurriculumNational Heart, Lung, And Blood Institute1999–2004

Professional Memberships

American Society of Clinical Oncology - ASCO
Fellow
American College of Physicians - ACP
Fellow

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment